BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Analyst Ratings
NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to BCLI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.75. This target is 962.78% above the current price.
BCLI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BCLI.
In the previous month the buy percentage consensus was at a similar level.
BCLI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-07-11 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-09-28 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-03-31 | Maxim Group | Maintains | Buy |